Table 4. Summary of HLA-A2 tetramer titrations in a subset of HLA-A2+ patients treated with the vaccine alone or in sequence with Cy.
| Patient | Tetramer Titration Patients without Cytoxan | Survival (mo) | |||
|---|---|---|---|---|---|
| MesoA2(531-539) | Tyrosinase | ||||
| pre | vaccine 3 | pre | vaccine 3 | ||
| 4 | 1:60 | 1:60 | 1:10 | 1:10 | 7.9 |
| 6 | 1:40 | >1:60 | 1:20 | 1:20 | 6.1 |
| 7 | 1:20 | 1:40 | 1:10 | 1:20 | 1.7 |
| Patient | Tetramer Titration Patients Given Cytoxan | Survival (mo) | |||
| MesoA2(531-539) | Tyrosinase | ||||
| pre | vaccine 3 | pre | vaccine 3 | ||
| 1 | 1:10 | 1:40 | 1:10 | 1:10 | 3.23 |
| 4 | 1:20 | >1:40 | 1:20 | 1:20 | 7.73 |
| 7 | 1:40 | 1:60 | 1:20 | 1:20 | 13.07 |
| 8 | >1:60 | 1:20 | 1:10 | 1:10 | 3.7 |
| 9 | >1:60 | >1:60 | 1:20 | 1:20 | 12.3 |
| 10 | 1:60 | <1:60 | 1:10 | 1:10 | 2.6 |
Pre = pre-vaccine #1, vaccine 3 = pre-vaccine #3. Patient PBL were labeled with HLA-A2 tetramers as described in the Methods section. Shown are the tetramer dilutions at which detectable tetramer staining was lost.